Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma

INTRODUCTION: Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell transplant or cytotoxic chemotherapy. CD19 has emerged as an attractive target in B-cell malignancy and is the subject of...

Descripción completa

Detalles Bibliográficos
Autores principales: Salles, Gilles, Długosz-Danecka, Monika, Ghesquières, Hervé, Jurczak, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363059/
https://www.ncbi.nlm.nih.gov/pubmed/33554668
http://dx.doi.org/10.1080/14712598.2021.1884677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363059/
https://www.ncbi.nlm.nih.gov/pubmed/33554668
http://dx.doi.org/10.1080/14712598.2021.1884677

Ejemplares similares